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Fas cell surface death receptor controls hepatic
lipid metabolism by regulating mitochondrial
function
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Muriel C. Fisser5,6, Tenagne D. Challa1,2, Eija Pirinen7,8, Youngsoo Kim9, Silvio Hemmi10, Erich Gulbins11,
Atan Gross12, Lorraine A. O’Reilly13,14, Markus Stoffel5,6, Johan Auwerx7 & Daniel Konrad1,2,4
Nonalcoholic fatty liver disease is one of the most prevalent metabolic disorders and it tightly
associates with obesity, type 2 diabetes, and cardiovascular disease. Reduced mitochondrial
lipid oxidation contributes to hepatic fatty acid accumulation. Here, we show that the Fas cell
surface death receptor (Fas/CD95/Apo-1) regulates hepatic mitochondrial metabolism.
Hepatic Fas overexpression in chow-fed mice compromises fatty acid oxidation, mitochon-
drial respiration, and the abundance of mitochondrial respiratory complexes promoting
hepatic lipid accumulation and insulin resistance. In line, hepatocyte-speciﬁc ablation of Fas
improves mitochondrial function and ameliorates high-fat-diet-induced hepatic steatosis,
glucose tolerance, and insulin resistance. Mechanistically, Fas impairs fatty acid oxidation via
the BH3 interacting-domain death agonist (BID). Mice with genetic or pharmacological
inhibition of BID are protected from Fas-mediated impairment of mitochondrial oxidation and
hepatic steatosis. We suggest Fas as a potential novel therapeutic target to treat obesity-
associated fatty liver and insulin resistance.
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Aberrant accumulation of lipids in the liver correlates withabdominal obesity and insulin resistance1. It constitutes ahallmark of nonalcoholic fatty liver disease (NAFLD),
which has emerged as the most common chronic liver disease in
the industrialized world affecting ∼30% of the adult population
and an increasing number of children2. The spectrum of NAFLD
ranges from simple nonprogressive fatty liver (hepatic steatosis)
to the potentially progressive nonalcoholic steatohepatitis, which
can proceed to ﬁbrosis, cirrhosis, and hepatocellular carcinoma3.
As NAFLD is becoming increasingly common in countries with
predominantly sedentary life styles, it is predicted to become the
leading indication for liver transplantation in the United States
within the next 5 years4. However, the molecular mechanisms
underlying the pathogenesis of obesity-associated fatty liver dis-
ease is poorly understood.
Fas (CD95/Apo-1) is a cell surface glycoprotein belonging to
the tumor necrosis factor (TNF) receptor superfamily and is
constitutively expressed in most tissues. Ligation of the Fas
receptor initiates proteolytic cleavage of intracellular caspases
culminating in apoptosis in many cell types. In addition to its
well-established role in apoptosis, activation of Fas can also
induce diverse nonapoptotic signaling pathways depending on
the tissue and conditions5. Evidence from animal and human
studies indicates that Fas and/or its ligand FasL are upregulated in
fatty liver disease6–8. Moreover, hepatocytes in fatty livers are
hypersensitive to Fas-mediated apoptosis causing hepatic injury
that eventually leads to cirrhosis and end-stage liver disease8.
Conversely, Fas antagonism tempers hepatocyte apoptosis and
liver damage. These studies indicated that Fas may mediate
increased susceptibility of NAFLD to end-stage liver disease such
as cirrhosis and liver carcinoma8. However, it is not known
whether Fas contributes to the development of hepatic lipid
accumulation. Furthermore, the metabolic consequence of Fas
activation in the liver has not yet been determined. In order to
assess a potential role of hepatic Fas in obesity-induced metabolic
dysregulation, mice with liver-speciﬁc Fas depletion or over-
expression were generated. Herein, we demonstrate that Fas
regulates hepatic mitochondrial function and fatty acid oxidation
and, hence, contributes to the development of hepatic steatosis.
Furthermore, pharmacological Fas depletion in the liver of obese
mice protects them from the development of hepatic steatosis and
insulin resistance, rendering Fas a promising novel therapeutic
target.
Results
Fas knockout in the liver reduces diet-induced steatosis. To test
a putative role of hepatic Fas activation in obesity-induced
metabolic dysregulation, liver-speciﬁc Fas-knockout mice
(Fasﬂox/ﬂox, Alb-Cre+/−; FasΔhep) were generated using the cre-lox
system9. As a control, littermate mice with ﬂoxed Fas but
absent Cre-recombinase (Cre) expression were used (Fasﬂox/ﬂox,
Alb-Cre−/−; FasF/F). Western blot analysis conﬁrmed depletion of
Fas protein speciﬁcally in the liver of FasΔhep mice whereas it was
unchanged in all other tissues analyzed (Supplementary Fig. 1a).
In order to investigate the physiological signiﬁcance of
hepatocyte-speciﬁc Fas depletion, mice were fed either standard
chow or high-fat diet (HFD) for 6 weeks. Total body weight gain
was similar in FasΔhep and their Cre-negative littermates under
each diet (Fig. 1a). Similarly, no differences were observed in fat
pad weights (Supplementary Fig. 1b). Metabolic phenotyping
revealed comparable food intake, metabolic rate, respiratory
quotient, and locomotor activity in both genotypes (Supple-
mentary Fig. 1c). Importantly, accumulation of hepatic lipid
droplets was reduced in HFD-fed FasΔhep mice as assessed by
histological analysis (Fig. 1b). Consistently, hepatic triglyceride
(TG) content was signiﬁcantly lower in HFD-fed FasΔhep com-
pared to FasF/F mice (Fig. 1c). Intrahepatic accumulation of TGs
generates various deleterious lipid intermediates, including cer-
amide and diacylglycerols (DAGs). Both lipids may interfere with
canonical insulin signaling, thus possibly affecting insulin sensi-
tivity10, 11. Notably, ceramide and DAG levels were signiﬁcantly
reduced in the liver of HFD-fed FasΔhep compared to control
mice (Fig. 1c). In contrast, neither plasma TG nor free-fatty acid
(FFA) levels differed between both groups (Table 1). Similarly,
circulating insulin, adiponectin, and leptin concentrations were
unchanged (Table 1). Of note, similar serum concentrations of
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) (Supplementary Fig. 1d) as well as similar hepatic protein
levels of cleaved caspase 3 and poly (ADP-ribose) polymerase
(PARP) (Supplementary Fig. 1e) were detected, suggesting a
similar degree of activation of the apoptotic pathway in both
groups of HFD-fed mice. In addition, plasma and hepatic
proinﬂammatory proﬁle was not signiﬁcantly altered in HFD-fed
FasΔhep mice (Supplementary Fig. 1f, g).
The storage of excess lipids in insulin-sensitive organs is
strongly associated with deteriorated glucose tolerance and
insulin resistance11. HFD feeding for 6 weeks impaired glucose
tolerance in FasF/F compared to chow-fed mice. Strikingly,
FasΔhep mice were partly protected from deteriorated glucose
metabolism (Fig. 1d). Lower gluconeogenic conversion of
pyruvate to glucose as assessed by the pyruvate tolerance test
further conﬁrmed improved glucose homeostasis in HFD-fed
FasΔhep mice (Fig. 1e). To assess insulin sensitivity in HFD-fed
mice, hyperinsulinemic-euglycemic clamp studies were per-
formed. A signiﬁcantly increased glucose infusion rate in HFD-
fed FasΔhep compared to FasF/F mice was noted, consistent with
improved whole-body insulin sensitivity (Fig. 1f and Supplemen-
tary Fig. 1h, i). Importantly, endogenous glucose production
under hyperinsulinemic clamp conditions was signiﬁcantly
reduced in the absence of hepatic Fas compared to control
littermates indicating improved hepatic insulin sensitivity
(Fig. 1f). In contrast, the insulin-stimulated glucose disposal rate
did not differ between either genotype, suggesting similar muscle
insulin sensitivity (Supplementary Fig. 1j, k). Corroborating
this ﬁnding, insulin-stimulated Akt (Thr308) phosphorylation
was elevated in liver lysates from HFD-fed FasΔhep compared to
FasF/F mice (Fig. 1g and Supplementary Fig. 1l). Collectively,
these results indicate that hepatic Fas depletion protects mice at
least partly from obesity-induced lipid accumulation and insulin
resistance in the liver.
Fas overexpression leads to steatosis and insulin resistance. To
examine whether hepatic Fas expression is sufﬁcient to induce
liver lipid accumulation and insulin resistance, C57BL/6J mice
were injected with an adenoviral vector expressing Fas (Ad-Fas).
Fas protein levels were ∼1.8-fold higher in livers of mice receiving
Ad-Fas compared to mice receiving a control vector expressing
lacZ (Ad-lacZ) (Fig. 2a). At 12 days after injection, body weight
was similar in both groups of mice (Fig. 2b), whereas blood
glucose but not plasma insulin, TG, and FFA levels were
increased in Fas-overexpressing mice (Supplementary Fig. 2a).
Hepatic Fas overexpression resulted in hepatic steatosis as
demonstrated by a signiﬁcant higher TG content (Fig. 2c).
Moreover, lipid intermediates such as ceramide and DAG accu-
mulated in livers of Ad-Fas mice (Fig. 2c). An intraperitoneal
glucose tolerance test was impaired (Fig. 2d) and
hyperinsulinemic-euglycemic clamp studies revealed signiﬁcantly
decreased glucose infusion rate and, importantly, higher
endogenous glucose production under clamp conditions in
Ad-Fas-injected vs. control animals (Fig. 2e and Supplementary
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Fig. 2b–d). In line with impaired hepatic insulin sensitivity,
insulin-stimulated hepatic Akt (Thr308) phosphorylation was
signiﬁcantly diminished in Ad-Fas compared to control Ad-lacZ
mice (Fig. 2f and Supplementary Fig. 2e). Taken together, hepatic
Fas overexpression was sufﬁcient to induce steatosis and impaired
insulin sensitivity, suggesting that Fas is a potent regulator of both
hepatic lipid metabolism and insulin sensitivity.
Fas regulates mitochondrial function. Hepatic steatosis may be
the result of reduced lipid oxidation12–14. In order to determine
whether Fas activation may impair mitochondrial fatty acid oxi-
dation, we measured oleic acid oxidation in liver homogenates of
Fas-overexpressing mice. Oleic acid oxidation rates were sig-
niﬁcantly decreased by ∼22% in Ad-Fas-treated mice (Fig. 3a).
However, mitochondrial DNA abundance was not changed
(Supplementary Fig. 3a), suggesting that Fas-mediated reduction
in hepatic mitochondrial function is not due to decreased mito-
chondrial number. Of note, Ad-Fas injection did neither induce
cytochrome c release nor increase cleavage of caspase 3 in the
liver (Supplementary Fig. 3b, c). In agreement with such notion,
protein levels of the large fragment of PARP, which result from
caspase cleavage and is involved in DNA damage detection and
repair, were comparable between Ad-Fas and Ad-lacZ mice
(Supplementary Fig. 3d), suggesting that impaired mitochondrial
function is not the result of induced apoptosis.
Table 1 Phenotypic characteristics of chow- and HFD-fed FasF/F and FasΔhep mice
FasF/F chow FasΔhep chow FasF/F HFD FasΔhep HFD
Glucose (mmol/l) 9.2± 0.5 (n= 5) 7.7± 0.4 (n= 6) 10.6± 0.5 (n= 9) 10.3± 0.5## (n= 8)
Insulin (pmol/l) 165± 26 (n= 5) 145± 21 (n= 5) 332± 29## (n= 9) 264± 31 (n= 6)
FFA (mmol/l) 0.57± 0.06 (n= 5) 0.64± 0.13 (n= 6) 0.82± 0.06 (n= 9) 0.77± 0.07 (n= 8)
TG (mg/dl) 66.2± 5.9 (n= 5) 60.9± 4.3 (n= 6) 86.5± 6.2 (n= 9) 82.8± 6.8 (n= 8)
Adiponectin (µg/ml) 7.2± 0.7 (n= 5) 7.1± 0.3 (n= 6) 6.2± 0.4 (n= 9) 5.7± 0.3 (n= 8)
Leptin (pg/ml) 131± 44 (n= 5) 65± 14 (n= 6) 436± 87# (n= 9) 338± 37# (n= 8)
Mice were fasted for 5 h before blood sampling. Values are expressed as mean±s.e.m.
#P< 0.05 and ##p< 0.01 indicate signiﬁcant differences between diets of the same genotype (ANOVA)
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Besides a reduction in lipid oxidation, elevated de novo
lipogenesis, increased fatty acid uptake, or blunted TG secretion
may contribute to hepatic steatosis1, 15. In hepatic Fas-
overexpressing mice, protein levels of the active form of the
lipogenic transcription factor sterol regulatory element-binding
protein 1 (SREBP1) was slightly lower (Supplementary Fig. 3e). In
addition, hepatic mRNA expression of key genes involved in
lipogenesis and fatty acid transport were unchanged or reduced in
Ad-Fas compared to Ad-LacZ mice (Supplementary Fig. 3f),
suggesting that neither de novo lipogenesis nor fatty acid uptake
was signiﬁcantly affected by hepatic Fas overexpression. However,
hepatic triglycerides secretion as measured by Triton-induced
hypertriglyceridemia was signiﬁcantly reduced in Ad-Fas com-
pared to Ad-LacZ mice (Supplementary Fig. 3g). Similarly,
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steady-state mRNA levels of microsomal triglyceride transfer
protein (Mttp), a key protein involved in triglyceride secretion16
(Supplementary Fig. 3f), were slightly reduced. In HFD-fed
FasΔhep mice, cleaved SREBP1 protein and transcript levels of
aforementioned genes including Mttp were unchanged when
compared to FasF/F mice (Supplementary Fig. 3h, i). Thus, the
development of Fas-mediated hepatic steatosis may mainly result
from impaired mitochondrial function.
To further substantiate such hypothesis, oxygen consumption
was analyzed in liver tissue from Ad-Fas mice by high-resolution
respirometry. Oxygen consumption rate driven by succinate was
signiﬁcantly lower in liver mitochondria of Ad-Fas compared to
Ad-lacZ mice, indicating reduced complex II-driven respiration
in these mice (Fig. 3b). To elucidate whether Fas compromises the
expression levels and activity of the respiratory chain complexes,
blue native (BN) polyacrylamide gel electrophoresis (PAGE)
analysis and in-gel activity assays of hepatic mitochondrial
complexes were performed. Increased hepatic Fas expression
signiﬁcantly reduced the abundance of complexes I, III, V
(Fig. 3c). More importantly, the activity of complex II, and
complexes I and IV, both individually and in supercomplexes
decreased upon Fas overexpression (Fig. 3d). Conversely, Fas
ablation in hepatocytes had the opposite effect: the abundance of
complex I and, to a lesser extent, of complex III was increased in
obese FasΔhep mice compared to FasF/Fcontrols (Supplementary
Fig. 3j). Taken together, these results suggest that Fas not only
impairs fatty acid oxidation in hepatocytes but also affects
abundance and function of mitochondrial complexes.
Fas impairs mitochondrial function BID-dependently.
Fas induces caspase 8-mediated cleavage of the BH3
interacting-domain death agonist (BID), thereby triggering
mitochondrial outer membrane permeabilization, leading
to mitochondrial damage17, 18. Hence, Fas activation may induce
mitochondrial dysfunction and decrease lipid oxidation in a
BID-dependent manner. Indeed, hepatic overexpression of Fas
in vivo induced cleavage of caspase 8 as well as BID (Fig. 4a, b
and Supplementary Fig. 4a, b). To address a potential role of BID
in mediating the effect of Fas on mitochondrial function, Fas was
overexpressed in hepatocytes of BID knockout (KO) mice. Of
note, BID ablation protected mice from Fas-induced deterioration
in glucose tolerance (Fig. 4c), whereas glucose tolerance was
similar in wild-type (WT) and BID KO mice upon lacZ injection
(Supplementary Fig. 4c). In line with such ﬁnding, liver TG levels
of Ad-Fas-treated BID KO mice were signiﬁcantly lower com-
pared to Ad-Fas-treated WT mice and comparable to Ad-lacZ
controls (Fig. 4d). Furthermore, mitochondrial complex II-driven
respiration was increased in Fas-overexpressing BID KO mice
(Fig. 4e). Importantly, treatment with antisense oligonucleotides
(ASO) targeting BID, which reduced hepatic BID protein content
by ∼60% (Supplementary Fig. 4d), improved glucose tolerance
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and reduced liver TG levels in mice overexpressing Fas in
hepatocytes (Fig. 4f, g). These ﬁndings strongly support a
mechanistic role for BID in mediating the inhibitory effect of Fas
on mitochondrial fatty acid oxidation.
In addition, Fas signaling may impact on liver lipid metabolism
via activation of acid sphingomyelinase (ASM), which catalyzes
the hydrolysis of sphingomyelin to ceramide in various cell
types19, 20. Therefore, Fas may directly induce the synthesis of
toxic lipid metabolites such as ceramide, which in turn may
induce hepatic insulin resistance and steatosis. However, ASM
activity was not altered in mice with adenovirus-mediated
increased hepatic Fas expression (Supplementary Fig. 4e).
Accordingly, glucose tolerance as well as liver TG content were
similar in hepatic Fas-overexpressing ASM KO mice compared to
WT mice (Supplementary Fig. 4f, g), suggesting that ASM
activation does not contribute to Fas-mediated changes in hepatic
metabolism. In summary, Fas activation reduces mitochondrial
function and fatty acid oxidation in hepatocytes in BID-
dependent manner.
Pharmacological depletion of Fas ameliorates steatosis. To
explore the therapeutic potential of targeting hepatic Fas signaling
to improve hepatic steatosis and insulin resistance, obese WT
mice were treated with ASO against Fas21. In a ﬁrst set of
experiments, C57BL/6J littermate mice were fed a HFD for
20 weeks and during the last 10 weeks of HFD received either
Fas-ASO or eight-base mismatch control oligonucleotide (con-
trol-ASO) once a week. Fas-ASO treatment reduced hepatic Fas
protein content by ∼90% compared to control-ASO (Supple-
mentary Fig. 5a). Hepatic Fas depletion did not affect body
weight, but was associated with lower blood glucose, plasma
insulin, FFA, and TG concentrations (Table 2). Importantly, liver
TG levels were signiﬁcantly lower (Fig. 5a) and glucose tolerance
signiﬁcantly improved in HFD-fed Fas-ASO-treated mice
(Fig. 5b). Consistent with ﬁndings in genetically Fas-depleted
mice, pharmacological depletion of hepatic Fas signaling
signiﬁcantly increased mitochondrial respiration (Fig. 5c).
Moreover, mitochondrial DNA abundance was increased in
Fas-ASO-treated mice (Fig. 5d), suggesting that Fas silencing
resulted in increased mitochondrial number. Finally, the expres-
sion of mitochondrial complex I and complex V was increased in
HFD-fed mice upon pharmacological Fas silencing (Fig. 5e).
In a second set of ASO experiments, leptin-deﬁcient ob/obmice
received either Fas-ASO or control-ASO twice a week for a total
of 4 weeks. Importantly, Fas-ASO-treated ob/ob mice also
displayed signiﬁcantly lower hepatic TG concentrations (Fig. 5f)
as well as improved glucose tolerance (Fig. 5g). Moreover, the
glucose infusion rate was signiﬁcantly increased and endogenous
glucose production under clamp conditions was lower in Fas-
depleted ob/ob mice (Fig. 5h and Supplementary Fig. 5b–d)
indicating improved hepatic insulin sensitivity. As outlined above,
fatty liver disease is associated with elevated FasL levels. Of note,
deﬁciency of secreted FasL22 in obese mice (HFD-fed FasLΔs/Δs
mice) reduced liver triglyceride levels (Supplementary Fig. 6).
Collectively, these data provide strong evidence that hepatic Fas
signaling may be a pharmacological target to treat fatty liver
disease and to improve hepatic insulin sensitivity.
Discussion
Dysregulated hepatic lipid metabolism plays an important role
in various metabolic diseases. Particularly, aberrant accumulation
of lipids may impair hepatocyte function promoting liver injury
and insulin resistance23, 24. The present study identiﬁes Fas as
a physiological regulator of hepatic mitochondrial function.
Furthermore, it suggests that Fas activation in hepatocytes con-
tributes to obesity-associated fatty liver and insulin resistance by
impairing mitochondrial fatty acid oxidation.
Mitochondrial fatty acid oxidation is the dominant oxidative
pathway for the removal of fatty acids under normal physiological
conditions23, and its impairment may result in the accumulation
of liver lipids and, thus, lead to NAFLD12–14. Herein, we show
that increased hepatic Fas expression compromised mitochon-
drial fatty acid oxidation, respiration, and the abundance of
respiratory complexes. Conversely, depletion of hepatic Fas
enhanced mitochondrial respiration and the abundance of
respiratory complexes. Changes in TG, ceramide, and DAG levels
in the liver paralleled observed alterations in mitochondrial
function. Such ﬁndings support the notion that impaired mito-
chondrial fatty acid oxidation leads to accumulation of toxic
lipids such as ceramide and DAG10, 25. Recent studies have
postulated that the latter may interfere with the insulin signaling
cascade, thereby causing insulin resistance10, 11. Consistently, we
present herein that increased hepatic Fas expression induced both
ceramide and DAG formation, which was associated with per-
turbed insulin signaling and increased hepatic insulin resistance.
On the other hand, hepatocyte-speciﬁc Fas-depleted obese mice
had reduced levels of ceramide and DAG in the liver and were
protected from the development of HFD-induced hepatic insulin
resistance. Interestingly, besides the detrimental effect of cer-
amide on insulin signaling and, thus, insulin sensitivity, in vitro
studies revealed a negative effect of ceramides on mitochondrial
respiration26, 27 that may further promote its own accumulation
and, thus, the creation of a vicious cycle. Of note, similar
expression levels of genes involved in de novo lipogenesis and
fatty acid transport further support a major role of altered
mitochondrial function in the observed liver phenotypes. How-
ever, we cannot fully exclude that other pathways involved in
hepatic lipid metabolism contributed to Fas-mediated hepatic
steatosis. In fact, Ad-Fas-injected mice revealed reduced trigly-
ceride secretion, possibly contributing to elevated liver steatosis in
these mice.
Fas ligation is well known to induce a cell-intrinsic apoptotic
pathway resulting in mitochondrial damage. Activation of Fas
induces caspase 8-mediated cleavage of the BH3-only BID protein
to the cleaved form cBID, which then translocates to the mito-
chondria to activate Bax and Bak, resulting in mitochondrial
outer membrane permeabilization and cytochrome c release18, 28.
Thus, this mechanism postulates a direct effect of Fas on mito-
chondrial function and, consequently, accumulation of hepatic
lipid metabolites. In accordance with such notion, hepatic over-
expression of Fas in vivo induced cleavage of caspase 8 as well as
BID and impaired oleic acid oxidation. BID-deﬁcient mice were
protected from Fas-induced mitochondrial dysfunction and
hepatic steatosis. Consistently, BID-deﬁcient mice were pre-
viously found to be protected from HFD-induced hepatic lipid
accumulation29. Thus, Fas inhibits mitochondrial fatty acid
Table 2 Phenotypic characteristics of long-term HFD-fed
mice treated with antisense oligonucleotides (ASO) against
Fas
Control-ASO Fas-ASO
Body weight (g) 37.4± 2.1 34.6± 2.6
Glucose (mmol/l) 9.7± 0.5 8.4± 0.4#
Insulin (pmol/l) 483± 78 236± 42*
FFA (mmol/l) 0.49± 0.03 0.39± 0.03*
TG (mg/dl) 85.5± 3.7 54.7± 4.7***
Mice were fasted for 5 h before blood sampling. Values are expressed as mean±s.e.m., n= 5
*P< 0.05, ***p< 0.001, and #p= 0.08 (Student’s t-test)
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oxidation via BID, thereby contributing to the pathogenesis of
obesity-associated hepatic steatosis. Of note, mice with
hepatocyte-speciﬁc caspase 8 deﬁciency are protected from the
development of methionine-and-choline deﬁcient diet-induced
steatosis30, further supporting a role of a Fas–caspase 8–BID
pathway in the pathogenesis of steatosis. Surprisingly, we could
neither detect increased cytochrome c release nor cleaved caspase
3 in livers of Fas-overexpressing mice. While we cannot exclude
that undetected apoptosis may be present in these mice, our data
indicate that the degree of Fas-mediated BID cleavage may not be
sufﬁcient to trigger cytochrome c release and subsequent cleavage
of caspase 3. Alternatively, increased protein levels of X-linked
inhibitor of apoptosis protein as observed in Ad-Fas-
overexpressing mice (1.0± 0.1 in Ad-lacZ vs. 1.6± 0.1 in Ad-
Fas, p< 0.01) may be responsible for lacking cleavage of caspase
3. Clearly, further studies are required to shed more light on the
complex molecular mechanisms involved in the activation of
BID-induced apoptotic signaling31.
ASOs are designed to bind to targeted mRNA by
Watson–Crick base pairing, resulting in modulation of its func-
tion through a variety of post-binding events32. Currently, mul-
tiple clinical trials using ASOs are ongoing, including the recent
FDA approval of KynamroTM for homozygous familial
hypercholesterolemia33 and Spinraza® for patients with spinal
muscular atrophy34. Therefore, ASO treatment has emerged as a
promising new approach to treat multiple diseases32, 35. Perti-
nently, it has been reported that mice treated with Fas-ASO
exhibited protection against agonistic Fas antibody-induced ful-
minant hepatitis. Consequently, it was suggested that Fas-ASO
may have therapeutic potential in liver disease21. We observed
herein that pharmacological Fas depletion in the liver of obese
mice with Fas-ASOs improved mitochondrial function and con-
comitantly protected them from the development of hepatic
steatosis and insulin resistance. Thus, our results extend the
potential use of Fas-ASO treatment to fatty liver disease, i.e., to
improve obesity-associated mitochondrial dysfunction, NAFLD,
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and insulin resistance. However, since Fas is a prototypical death-
inducing receptor and also a potential tumor suppressor that is
downregulated during cancer progression36, 37, the usefulness
of such Fas-ASO treatment may be limited. Of note, liver
morphology, ﬁbrosis (4.7± 0.6% Sirius red-positive area in FasF/F
vs. 4.9± 0.6% Sirius red-positive area in FasΔhep mice, p= 0.8),
as well as triglyceride levels (67± 5 µmol/g liver in FasF/F vs.
73± 2 µmol/g liver in FasΔhep mice, p= 0.2) were not altered in
18-month-old FasΔhep compared to FasF/F mice. Additionally,
loss of Fas was recently reported to reduce incidences of ovarian
and liver cancer as well as tumor size in mice38. Consistently, Fas
may promote the progression of fatty liver to cirrhosis, which is
associated with liver cancer8. Thus, Fas activation may have both
tumor-promoting and tumor-protective function. Clearly, further
studies are required to explore the potential role for Fas-ASO or
inhibitors of Fas signaling in the treatment of NAFLD and
(hepatic) insulin resistance as well as the safety of such
an approach. Of note, HFD-fed FasLΔs/Δs mice22 revealed
reduced liver triglyceride levels. Consequently, Fas-mediated lipid
accumulation in the liver may be induced by soluble FasL,
which pertinently was found to be upregulated in fatty liver
disease8. Interestingly, genetic deletion of TRAIL (TNF-related
apoptosis-inducing ligand) receptor in mice reduced HFD-
induced hepatic steatosis and insulin resistance39, suggesting
that other death receptors may affect hepatic metabolism in a
similar way.
In conclusion, our results reveal an important and unique role
for Fas in regulating hepatic mitochondrial function and lipid
metabolism. Pharmaceutical depletion of Fas or its signaling
pathway may therefore emerge as a promising new avenue in the
treatment of hepatic steatosis and insulin resistance.
Methods
Animals. C57BL/6J mice with exon 9 of Fas ﬂanked with LoxP sites were produced
as previously described40 and crossed with mice harboring the Cre-recombinase
transgene under the control of the albumin promoter (C57BL/6J-Tg(Alb-Cre)
mice) to generate hepatocyte-speciﬁc depletions (FasΔhep). Littermate mice with
ﬂoxed Fas but absent Cre-recombinase (Cre) expression were used as controls
(FasF/F). ASM KO mice on a C57BL/6N background41 and BID KO mice on a
C57BL/6J background18 were bred in our own facility. FasLΔs/Δs mice (C57BL/6J
background) were generated as previously described22 and ob/ob (C57BL/
6OlaHsd-Lep<ob>) mice were purchased from Harlan.
Male mice were used and housed in a speciﬁc pathogen-free environment in a
12 h light/dark cycle and fed ad libitum with regular chow diet (ProvimiKliba,
Kaiseraugst, Switzerland) or high-fat diet (58 kcal% fat w/sucrose Surwit Diet,
D12331, Research Diets, New Brunswick, NJ, USA). Experiments were performed
at the age of 10–12 weeks (FasΔhep and Ad-Fas mice), 26 weeks (ASO-treated
mice), or 8 weeks (ob/ob mice). For all animal experiments, the sample size
required to achieve adequate power was estimated on the basis of pilot work or
previous experiments. Mice that did not gain weight in diet-induced obesity
experiments were excluded. Where appropriate, experiments were performed in
weight- and sex-matched animals. All protocols conformed to the Swiss animal
protection laws and were issued by the Cantonal Veterinary Ofﬁce in Zurich to the
University Children’s Hospital Zurich, Switzerland. All experiments with FasLΔs/Δs
mice and control C57BL/6 mice were conducted at the Walter and Eliza Hall
Institute of Medical Research and were approved by the guidelines of the Walter
and Eliza Hall Institute of Medical Research Animals Ethics Committee, Victoria,
Australia.
Genotyping of animals. All mice were genotyped by PCR with primers amplifying
the Cre transgene (generating 310 bp Cre allele products and 510 bp control) and
Fas (generating 319 bp WT and 399 bp “ﬂoxed” allele products).
Recombinant adenoviruses. Ad5-based recombinant E1- and E3-deleted adeno-
virus vectors expressing mouse Fas (Ad-Fas) and β-galactosidase (Ad-lacZ) were
constructed and CsCl puriﬁed42. Viral titers were determined by plaque assay. Both
transgenes are controlled by the cytomegalovirus (CMV) promoter, and the CMV
promoter of Ad-Fas was modiﬁed to contain an upstream tet-repressor binding
site. Ad-Fas was generated and ampliﬁed in 911 helper cells expressing the
tet-repressor. Viruses were injected into the tail vein of 8–10-week-old C57BL/6J
mice at a dose of 1 × 109 plaque-forming units.
Mouse Fas ASO. ASOs were synthesized using an Applied Biosystems 380B
automated DNA synthesizer (Perkin Elmer–Applied Biosystems, Foster City, CA,
USA) and puriﬁed by ion-exchange high-performance liquid chromatography
(HPLC) using a linear gradient of buffers A and B. Buffer A: 50 mM NaHCO3,
buffer B: 1.5M NaBr, 50mM NaHCO3—both buffers in acetonitrile/water 3:7 (v:v).
Puriﬁed ASOs were desalted using C18 reverse-phase cartridges and analyzed by
HPLC. The ASO identiﬁcation numbers and sequences are as follows: mismatch
control oligonucleotide (control-ASO), ISIS 141923, 5′-CCTTCCCTGAAGGTT
CCTCC-3′; Fas-ASO, ISIS22023, 5′-TCCAGCACTTTCTTTTCCGG-3′, BID-ASO,
ISIS 119935, 5′-GACCATGTCCTGGCCAGAAA-3′. The backbone was comprised
of phosphorothioate and the ﬁrst and last ﬁve bases of the ASOs have a 2’-O-
methoxyethyl modiﬁcation. ASOs were resuspended and delivered in 0.9% saline.
HFD-fed C57BL/6J mice received 50 mg ASO/kg body weight once per week for
10 weeks or 4 consecutive days as described21; leptin-deﬁcient ob/ob (C57BL/
6OlaHSD-Lep<ob>) mice were treated with 50 mg/kg body weight twice a week
for 4 weeks. Mice with liver-speciﬁc Fas overexpression received 3 injections at
50 mg ASO/kg body weight per week starting 1 week before adenovirus injection.
Liver triglyceride measurement. Liver triglycerides were measured from 50 mg of
liver tissue according to the method of Bligh and Dyer43 and quantiﬁed with an
enzymatic assay (Roche Diagnostics, Rotkreuz, Switzerland). Prior to tissue col-
lection, mice were fasted for 5 h except for liver-speciﬁc Fas-knockout mice, which
were fasted overnight.
Liver triglyceride secretion. Ad-Fas mice were fasted for 6 h and injected intra-
venously with the lipase inhibitor tyloxapol (500 mg/kg; Sigma) prior to blood
collection at 0, 1, 2, 4, 6, and 24 h after injection. The collected blood samples were
used for TG measurements and the very low density lipoprotein–TG production
rate was calculated from the slope of the plasma TG vs. time curve.
Glucose and pyruvate tolerance test. Glucose (1 g/kg body weight for ob/ob
mice; 2 g/kg body weight for C57BL/6J) and pyruvate (2 g/kg body weight) were
injected intraperitoneally in overnight fasted mice and in mice fasted for 3 h,
respectively. Blood glucose concentration was measured in blood from tail-tip
bleedings using a glucometer (Accu-Check Aviva, Roche Diagnostics).
Hyperinsulinemic-euglycemic clamp studies. Hyperinsulinemic-euglycemic
clamp studies were performed in freely moving mice as described44. Insulin was
infused at a constant rate (18 mU/kg×min) and glucose infusion rate was calculated
once glucose infusion reached a more or less constant rate with blood glucose levels
at 5 mmol/l (∼80–100 min after the start of insulin infusion). Thereafter, blood
glucose was kept constant at 5 mmol/l for 20 min and glucose infusion rate was
calculated. The glucose disposal rate was calculated by dividing the rate of [3-3H]
glucose infusion by the plasma [3-3H]glucose-speciﬁc activity45, 46. Endogenous
glucose production during the clamp was calculated by subtracting the glucose
infusion rate from the glucose disposal rate45, 46. Insulin-stimulated glucose dis-
posal rate was calculated by subtracting basal endogenous glucose production
(equal to basal glucose disposal rate) from glucose disposal rate during the clamp47.
Ceramide and diacylglycerol analysis in liver tissue. Lipids were extracted from
∼30 mg frozen liver tissue according to the method of Bligh and Dyer43, with
50 mM potassium phosphate buffer in the aqueous layer and spiked with appro-
priate internal standards. Extracted samples were evaporated to dryness and
redissolved in methanol. The extracts were diluted 5 times in methanol/water
(4:1 v/v) with 10 mM ammonium acetate prior to liquid chromatography/tandem
mass spectrometry analysis to enhance chromatography and to induce ionization.
Chromatographic separation was performed on a nanoAcquity UPLC system
equipped with a HSS T3 column (Waters, Milford, MA, USA). The chromato-
graphic conditions were adopted from Castro-Perez et al.48. A Waters Synapt G2
HDMS mass spectrometer was employed for the analysis of the lipid composition.
Data acquisition and processing were performed with the MassLynx software
(Waters), and the targeted lipids were identiﬁed based on their exact mass using the
LipidBlast library and the NIST MSsearch software49.
Histology. Liver tissues were ﬁxed in 4% buffered formalin and embedded in
parafﬁn. Sections were cut and stained with hematoxylin and eosin.
Fatty acid oxidation. A piece of 100–200 mg liver tissue was homogenized in
sodium chloride-Tris-EDTA buffer, centrifuged at 420×g for 10 min at 4 °C,
and the supernatant was incubated for 40 min at 37 °C in a reaction mixture
containing14C-radiolabeled oleic acid, 2 mM ATP, 0.5 mM dithiothreitol, and
measured for acid-soluble metabolites and trapped CO2.
Oxygen consumption rate. Liver tissue was homogenized in mir05 medium
(EGTA 0.5 mM, MgCl2.6H2O 3 mM, K-lactobionate 60 mM, Taurine 20 mM,
KH2PO4 10 mM, HEPES 20 mM, Sucrose 110 mM, BSA, essentially fatty acid
free 1 g/l). Oxygen consumption rate was then assessed using high-resolution
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respirometry (Oroboros Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria).
Succinate (9.6 mM), ADP (4.8 mM), and rotenone (0.1 mM) were sequentially
added to stimulate complex II-driven oxygen consumption50.
Mitochondrial isolation. Liver tissue was homogenized in mitochondria isolation
buffer (IBc) that contains 10 ml of 0.1 M Tris-MOPS, 1 ml of EGTA/Tris and 20 ml
of 1M sucrose and 69 ml of distilled water, pH 7.4. Homogenates were centrifuged
at 600×g for 10 min at 4 °C to discard the debris leaving mitochondria in the
supernatant. Supernatant was spun down at 7,000×g for 10 min at 4 °C to pellet the
mitochondria. The pellets were washed once with 1 ml IBc. The mitochondria
pellet was used for blue native PAGE.
BN-PAGE and in-gel activity. A high-resolution BN-PAGE was performed to
analyze mitochondrial complexes expression and activity using the Native-PAGE
Novex Bis-Tris Gel system (Invitrogen, Buchs, Switzerland) according to the
manufacturer’s instructions. Mitochondria were isolated from liver tissue and
resuspended in Native-PAGE sample buffer containing 0.5% n-dodecyl-β-D-
maltoside (Invitrogen) for mitochondrial complexes’ expression or digitonin
(Thermo Fisher Scientiﬁc, Reinach, Switzerland) 4 g/g protein for activity. Equal
amounts of mitochondrial proteins as determined by Bradford protein assay
were loaded on a Native-PAGE Novex 3–12% gradient Bis-Tris acrylamide gel
(Invitrogen). Gels were transferred onto polyvinylidene diﬂuoride membranes
using iBlot gel transfer system (Thermo Fisher Scientiﬁc) and immunoblotted with
OxPhos complex antibody cocktail (Mitosciences, Eugene, OR, USA) or incubated
with substrate solutions to assess in-gel activity. Complex IV substrate solution: 50
mg diaminobenzidine, 100 mg cytochrome c, and 90 ml 50 mM phosphate buffer
pH 7.4 to 10 ml with double-distilled water (ddH2O). Same gel was washed with
water and then incubated with complex I substrate solution: 40 μl 1 M Tris-HCl,
pH 7.4, 2 mg NADH, 50 mg nitrotetrazolium blue chloride (NTB) to 20 ml with
ddH2O. Another gradient gel was used to assess complex II activity: 200 μl 1 M
sodium succinate, 25 mg NTB, 8 μl 250 mM phenazinemethosulfate (from 250mM
stock in dimethyl sulfoxide), 50 μl 1 M Tris-HCl to 10 ml with ddH2O. Reactions
were stopped by washing with 10% acetic acid for 5 min followed by water for
5 min. Gels were scanned at different time points of incubation to follow kinetics of
the signal before saturation.
Acid sphingomyelinase activity. Samples were shock frozen and lysed in 250 mM
sodium acetate (pH 5.0) and 1% NP40 for 15 min on ice. The samples were further
homogenized by two rounds of sonication for 10 s each using a tip sonicator.
Aliquots of the lysates were diluted to 250 mM sodium acetate (pH 5.0), 0.1% NP40
and incubated with 50 nCi per sample [14C]sphingomyelin (Perkin Elmer, Wal-
tham, MA, USA; 52 mCi/mmol) for 30 min at 37 °C. The substrate was dried prior
to the assay, resuspended in 250 mM sodium acetate (pH 5.0), 0.1% NP40, and
bath-sonicated for 10 min to promote the formation of micelles. The reaction was
stopped by the addition of 800 µL chloroform/methanol (2:1, v/v), phases were
separated by centrifugation, and an aliquot of the upper, aqueous phase was
measured by using liquid scintillation counting to determine the release of [14C]
phosphorylcholine from [14C]sphingomyelin as a measure of acid sphingomyeli-
nase activity.
Determination of plasma parameters. Plasma insulin and FFA levels were
determined as previously described51. Plasma leptin and cytokine levels were
determined with mouse Procarta Cytokine Assay Kit (Affymetrix). Plasma adi-
ponectin levels were measured with an ELISA kit (Axxora, San Diego, CA, USA).
Triglyceride concentrations were determined using a colorimetric assay (Sigma, St
Louis, MO, USA). ALT/AST levels were measured using a multiple biochemical
analyzer (Dri-Chem 4000i; Fujiﬁlm, Tokyo, Japan).
RNA extraction and quantitative reverse transcription-PCR. Total RNA was
extracted and reverse transcribed52. The following primers were used: Acox1,
Mm00443579_m1; CPT1α, Mm00550438_m1; ACC1 Mm01304289_m1; FAS
Mm00662319_m1; SCD-1 Mm01197142_m1; SREBP1c Mm00550338_m1; CD36
Mm00432403_m1; MTTP Mm00435015_m1; PPARα, Mm00627559_m1; KC,
Mm00433859_m1; MCP-1 Mm00441242_m1; TNFα, Mm00443258_m1; CD68,
Mm03047343_m1 (Applied Biosystems, Foster City, CA, USA).
Insulin signaling. After an overnight fast, mice were injected 5 units normal
human insulin (Actrapid, Novo Nordisk, Denmark) into the portal vein. Liver
samples were collected 2 min after injection and proteins were extracted from
tissues for western blot analysis.
Western blotting. Tissue samples were homogenized in a buffer containing
150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1% NP40, 0.25% sodium
deoxycholate, 1 mM sodium vanadate, 1 mM NaF, 10 mM sodium β-glyceropho-
sphate, 100 nM okadaic acid, 0.2 mM phenylmethylsulfonyl ﬂuoride, and a 1:1,000
dilution protease inhibitor cocktail (Sigma). Protein concentration was determined
using bicinchoninic acid assay and equivalent amounts of protein were resolved by
LDS-(lithium dodecyl sulfate)-PAGE (4–12% gel; NuPAGE, Invitrogen). Proteins
were transferred to a nitrocellulose membrane (0.2 μm, Bio-Rad) and blocked for 1
h in 5% non-fat dry milk (Bio-Rad) resolved in Tris-buffered saline, containing 1%
Tween-20. Membranes were incubated overnight at 4 °C on a rocking platform
with respective primary antibodies. The following primary antibodies were used:
anti-Fas (05–351; clone 7C10), anti-actin (MAB1501) (Millipore, Billerica, MA,
USA), anti-caspase 8 (ALX-804-448; 3B10) (Enzo Life Sciences, Farmingdale, NY,
USA), anti-cleaved caspase 3 (9661), anti-PARP (9542S), anti-cytochrome c (4272),
anti-HSP90 (4877), anti-Akt (9272) and anti-phospho-Akt (Thr308; 9275S) (Cell
Signaling, Danvers, MA, USA), anti-cleaved-Bid (ab10640) (Abcam, Cambridge,
UK), anti-Grp78 (sc-1051) (Santa Cruz Biotechnology, Dallas, TX, USA), anti-
SREBP1 (557036) (BD Biosciences, Allschwil, Switzerland), and anti-BID53.
Metabolic cage analysis. Locomotion, food and water intake, O2 consumption,
and CO2 production were determined for single-housed mice during a 24 h period
in a metabolic and behavioral monitoring system (PhenoMaster, TSE Systems, Bad
Homburg, Germany).
Data analysis. Data are presented as means±s.e.m. Data distribution was assessed
via Shapiro–Wilk test using SPSS 13.0 (Chicago, IL, USA). Normally distributed
data with similar variance between the groups were analyzed by unpaired two-
tailed Student’s t-test, one-way analysis of variance (ANOVA) with Tukey or
Newman–Keuls correction for multiple group comparisons or two-way ANOVA
with Bonferroni multiple comparisons. For nonparametric data the
Mann–Whitney test was used. All statistical tests were calculated using the
GraphPad Prism 5.04 (GraphPad Software, San Diego, CA, USA). P-values of
<0.05 were considered to be statistically signiﬁcant. Power calculation analysis was
not performed. The evaluator was blinded to the identity of a speciﬁc sample as far
as the nature of the experiment allowed it.
Data availability. The data supporting the ﬁndings of this study are available
within the article, its Supplementary Information ﬁles, or from the corresponding
author on reasonable request.
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